Luxshare Precision Releases 2025 Sustainability Report
CROWN HOLDINGS ANNOUNCES PUBLICATION OF ITS 2025 SUSTAINABILITY REPORT "DELIVERING SUSTAINABILITY", HIGHLIGHTING KEY MILESTONES AND PROGRESS TOWARD 2030 GOALS
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
The Toro Company Publishes 2025 Global Sustainability Impact Report
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
Immuneering (NASDAQ:IMRX) vs. GRI Bio (NASDAQ:GRI) Head-To-Head Survey
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF
GRI Bio Announces Reverse Stock Split
GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621
GRI Bio Announces Closing of $8.0 Million Public Offering
GRI Bio Announces Pricing of $8,000,000 Million Public Offering
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
Grainger says UK's Renters' Rights Bill 'provides stability for investors and landlords'
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment
Two Senior Executives from S&P and the Global Reporting Initiative (GRI) join the Diginex team
GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference
GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio to Participate in the Virtual Investor Closing Bell Series
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025
GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference
GRI Bio Announces Closing of $5.0 Million Public Offering
GRI Stock Down on Public Offering Despite Encouraging IPF Study Data
GRI Bio Announces Pricing of $5.0 Million Public Offering
Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan
GRI Bio Participates in a Virtual Investor CEO Connect Segment
GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule
GRI Bio Announces Reverse Stock Split
GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds
GRI Bio to Participate in the Virtual Investor Closing Bell Series
GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024
GRI Bio Announces Exercise of Warrants
GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)